May 7th 2024
If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Arap and Pasqualini Join Oncology Leadership at Rutgers Cancer Institute of New Jersey
February 21st 2018The Rutgers Cancer Institute of New Jersey has announced 2 new additions to its team of oncology leaders. Wadih Arap, MD, PhD, will serve as the new director of the Rutgers Cancer Institute of New Jersey at University Hospital, and Renata Pasqualini, PhD, will serve as the chief of the Division of Cancer Biology in the Department of Radiation Oncology at Rutgers New Jersey Medical School.
Read More
Jean-Charles Soria to Receive TAT 2018 Honorary Award for Cancer Drug Development
February 20th 2018Jean-Charles Soria, MD, PhD, will be honored with the Targeted Anticancer Therapies 2018 Honorary Award for cancer drug development. Soria has played a large part in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy for the last 15 years.
Read More
Identifying and Managing Immune-Related Adverse Events
February 20th 2018As checkpoint inhibition is increasingly being utilized beyond the scope of clinical trials, it’s essential that community-based oncologists and physicians learn how to quickly diagnose and treat immune-related adverse events.
Read More
Abscopal Effect of Radiotherapy: Reality or Urban Legend?
February 20th 2018<strong>IN THIS ISSUE, INVESTIGATORS FROM</strong> Emory Winship Cancer Institute describe their experience with the so-called “abscopal effect,” which describes the ability of locally delivered radiation therapy to trigger distant antitumor effects. R. H. Mole, BM, FRCP, first coined the term abscopal effect as “an action at a distance from the irradiated volume but within the same organism” in 1953.
Read More
ACCC Trends Survey: New Technology Is a Boon and a Bane
February 16th 2018The rising costs of drugs continue to impede cancer program growth, and new technology remains a boon and a bane, depending on its utility for expanding practice capability or its inflexibility to needs, according to the 2017 Trending Now in Cancer Care Survey from the Association of Community Cancer Centers, based in Rockville, Maryland.
Read More
Abscopal Effect Induction Among Patients With Metastatic Non-Small Cell Lung Cancer
February 14th 2018The prognosis for patients with metastatic non–small cell lung cancer (NSCLC) is poor. However, with recent trials showing improved overall survival with checkpoint inhibitors compared with standard chemotherapy, disease management is changing.
Read More
Confirmed Benefit of Pembrolizumab in Urothelial Cancer With KEYNOTE-045 2-Year Follow-Up
February 11th 2018Updated findings from the phase III KEYNOTE-045 trial confirmed the benefit of pembrolizumab (Keytruda) compared with chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer. Two-year follow-up of the trial presented at the 2018 Genitourinary Cancers Symposium demonstrated that overall survival was improved with pembrolizumab.
Read More
Immunotherapy Combination Boosts PFS for Treatment of High TMB NSCLC
February 9th 2018Based on data from part 1a of the phase III CheckMate-227 trial, nivolumab (Opdivo) and ipilimumab (Yervoy) in combination show improved progression-free survival (PFS) versus with chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB) non–small cell lung cancer (NSCLC).
Read More
Immunotherapy Linked to Hyperprogression of NSCLC and Other Cancers
December 21st 2017Hyperprogressive disease (HPD) after immunotherapy treatment may not be as rare of a phenomenon as previously thought. A recent multicenter, retrospective analysis of 242 patients with advanced non–small cell lung cancer (NSCLC) found that 16% of patients developed hyperprogression during anti–PD-1/ PD-L1 treatment.<sup>1</sup> The study, which was presented at the 2017 ESMO Annual Congress, is one of the latest to highlight the risk of hyperprogression.
Read More
Rationale Grows for the Immune-Related Response Criteria
December 20th 2017The overwhelming majority of patients with cancer who appear to progress after they begin immunotherapy will never respond. They will continue to progress, just as quickly as they would with no treatment and just as predicted by the Response Evaluation Criteria in Standard Tumors (RECIST) criteria that have long guided most trial evaluations and many treatment decisions.
Read More
Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC
December 19th 2017An extension in overall survival (OS) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has completely changed the standard of care for patients with metastatic renal cell carcinoma (mRCC), Thomas Powles, MD, MBBS, MRCP, told audience members during the 9th European Multidisciplinary Meeting on Urological Cancers.<br />
Read More
Blackwell Inaugurated as VP of Early Phase Development and Immuno-Oncology at Lilly
December 14th 2017Eli Lilly and Company has announced that Kimberly L. Blackwell, MD, a pioneer in breast cancer research, will serve as its vice president of early phase development and immuno-oncology. She will begin her new role on March 12, 2018.<br />
Read More
Exciting Response Rates Seen in Updates Findings of bb2121 in Multiple Myeloma
December 13th 2017Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission. <br />
Read More
Brentuximab Vedotin/Nivolumab Combo Promising for Relapsed/Refractory Hodgkin Lymphoma
December 13th 2017The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) demonstrated promising clinical activity in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I/II trial presented at the 2017 ASH Annual Meeting.
Read More
Pembrolizumab Receives FDA's Priority Review in PMBCL
December 12th 2017Pembrolizumab (Keytruda) has received a priority review from the FDA for a supplemental biologics license application (sBLA) for the treatment of adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL), according to a press release from Merck, the manufacturer of pembrolizumab. The findings were first presented at the 14th International Conference on Malignant Lymphoma and updated data were recently presented at the 2017 ASH Annual Meeting.
Read More
Liso-Cel Shows Potent, Durable Remissions in High-Risk DLBCL
December 12th 2017Updated results from the TRANSCEND study demonstrated that liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an 81% objective response rate and a 63% complete remission rate in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Pembrolizumab/Trastuzumab Combo Generates Activity in Trastuzumab-Resistant Breast Cancer Subgroup
December 7th 2017In results from the phase Ib/II PANACEA trial presented at the 2017 San Antonio Breast Cancer Symposium (SABCS), the combination of pembrolizumab (Keytruda) and trastuzumab (Herceptin) achieved an objective response rate (ORR) of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.
Read More
Nivolumab/Ipilimumab Combo May Hold Potential in Neoadjuvant Melanoma
November 12th 2017The objective response rate with neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) was almost tripled compared with nivolumab alone in patients with high-risk resectable melanoma, according to preliminary findings from a phase II study presented during the 32nd SITC Annual Meeting.
Read More
Four Dana-Farber Researchers to Join Parker Institute
October 23rd 2017Four researchers from the Dana-Farber Cancer Institute are joining the Parker Institute for Cancer Immunotherapy as a result of a collaboration between the 2 institutions: W. Nick Haining, BCh, BM; Catherine Wu, MD; Philip Kranzusch, PhD; and F. Stephen Hodi, Jr., MD.
Read More